Rayscape

Deep learning image analysis is the entire offering, spanning chest radiograph interpretation and lung nodule detection on CT with no hardware, PACS, or services layer of its own. The company is small, reported at roughly 26 employees, which reinforces rather than undermines the point: there is no adjacent business the algorithms are decorating.

Assistive detection with an interesting wrinkle worth noting. The reporting engine converts detections into draft narrative documentation for radiologist review and validation, which the company frames explicitly as preserving physician oversight while reducing transcription. Separately, the company co-authored research on how textual versus visual AI explanations affect reader decision making, which indicates unusual awareness that HOW a result is presented changes whether a clinician defers to it. That is a more sophisticated read of the oversight problem than most vendors demonstrate.

The company publishes research rather than only claims, including work on the capabilities and evidence coverage of CE-marked AI products for lung nodule analysis, effectively surveying its own competitive category, and contributing to a study on how explanation format affects clinical decision making. Threshold sensitivity is acknowledged openly, with the tuberculosis work highlighting the importance of tailored threshold settings, which is an honest admission that out-of-the-box performance depends on local configuration. Model architecture, training data composition, and per-finding accuracy across the claimed 148 findings are not published.

One genuinely strong independent evidence point anchors this. Performance was assessed in a computer-aided tuberculosis detection study within a South African tuberculosis prevalence survey published in The Lancet Digital Health, which is both a high impact venue and a population screening setting rather than a curated retrospective cohort. That is materially more rigorous than vendor-run accuracy testing. Against that, the claim of detecting up to 148 pathologies on chest X-ray is not matched by per-finding published performance, and user reported figures such as up to 50 percent reduction in comparative study analysis time are anecdotal. Strong evidence where it exists, thin across the breadth claimed.

No specific PHI handling or data governance framework was located in the materials reviewed.

No HIPAA or BAA commitment was located. A Romania headquartered vendor without FDA clearance is not positioned for US clinical sale, so the question is largely prospective.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located in the materials reviewed.

CE marked and externally evaluated, with no FDA clearance located. Graded C on the same basis as Aiforia, Visiopharm, Mindpeak, Stratipath, and Primaa: real European authorization without US clinical clearance. The tuberculosis focus is worth reading alongside this, since the highest value deployments for chest X-ray TB screening are in high burden countries outside the US and Europe, where CE marking plus WHO aligned evidence often matters more commercially than FDA clearance does.

Stronger than most small vendors, driven by where the evidence was generated. Validation within a South African tuberculosis prevalence survey tests the algorithm on a population and disease burden profile very different from the European and North American cohorts that dominate imaging AI training data, which is a direct test of the generalization gap that most vendors leave unexamined. The company also publicly acknowledges that threshold settings need tailoring for diagnostic efficiency, which is an honest statement about performance varying by deployment context. No formal governance framework or demographic subgroup breakdown was located.

Integrates directly into on-premise or cloud PACS, returning annotated images and structured outputs inside the native radiology viewer with no parallel workspace, and the interface is described as configurable so institutions can align outputs, thresholds, and visualization with local reporting standards. Configurable thresholds are an unusual and genuinely useful integration feature, since it lets a site tune sensitivity to its own case mix. No named connector list or API documentation was located. Radiology environment integration; no EHR integration claimed.

Both on-premise and cloud PACS integration are offered, described as a plug-and-scan model. Offering an on-premise path is meaningful for institutions that cannot export imaging, and is particularly relevant given the company's tuberculosis screening footprint in settings where data export may face regulatory or connectivity constraints. Specific tenancy and residency terms for the cloud path are not published.

No pricing, licensing structure, or commercial model detail was located in the materials reviewed. The company is early stage, reporting a seed round in March 2024 and roughly 26 employees, so a buyer should weigh vendor durability alongside product fit, particularly given that another vendor in this same lane entered administration in 2025.

Thoracic focused across two modalities: chest radiography with a claimed 148 findings, and lung nodule detection on CT with automatic longitudinal comparison across a patient's prior scans to track disease evolution. The longitudinal comparison capability is a real differentiator, since lung cancer screening depends on measuring nodule change over time rather than single timepoint detection, and most competitors handle only the latter. Tuberculosis detection extends the relevance to global public health screening programmes. Confined to the chest.